Risk for Suicidal Thoughts Increased in Teens With Persistent Withdrawn Behaviors
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
TUESDAY, Jan. 30, 2024 -- Persistent withdrawn symptoms and increasing somatic symptoms during early to mid adolescence are associated with an increased risk for suicidal thoughts in mid adolescence, according to a study published online Jan. 25 in JAMA Network Open.
Akito Uno, M.D., from the University of Tokyo, and colleagues assessed which categories and trajectories of psychopathological and behavioral symptoms are associated with suicidal thoughts in adolescence. The analysis included data from three waves of the Tokyo Teen Cohort study (2,780 adolescents) conducted at ages 10, 12, and 16 years from October 2012 to September 2021.
The researchers found that 8.2 percent of participants had suicidal thoughts. When adjusting for each symptom trajectory and confounders, adolescents with persistent high withdrawn symptoms (odds ratio, 1.88) and increasing somatic symptoms (odds ratio, 1.97) had a significantly higher risk for suicidal thoughts versus adolescents without these symptoms. For the risk for suicidal thoughts, there was no interaction between these symptom trajectories.
"A wide range of people involved in adolescent health should pay attention to the suicidal risk associated with these symptoms and consider the possibility of providing psychosocial support, particularly when the symptoms persist or increase in the longitudinal follow-up," the authors write.
One author disclosed financial ties to industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-01-31 02:15
Read more
- FDA Approves Vyloy (zolbetuximab-clzb) for the Treatment of Advanced Gastric and GEJ Cancer
- What You Need to Know About FluMist, the Nasal Flu Vaccine
- Recreational Cannabis Legalization Tied to Higher Prenatal Use
- Novo Nordisk CEO Warns of Deaths Linked to Compounded Semaglutide
- USPSTF Recommends Screening for Domestic Violence in Pregnant, Postpartum Women
- ASA: Fibrinogen-to-Albumin Ratio Is Risk Factor for Preeclampsia
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions